The system is expected to strengthen into a tropical storm by the end of the day and continue strengthening if it remains ...

Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.

The obesity medicines market has so far been dominated by Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound, noted Bloomberg, which also points out that Viking Therapeutics (VKTX ...

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial. Compared to patients ...

Wegovy is a weight loss medication that you can only get with a prescription from a licensed healthcare professional. Learn more about who is eligible and what to expect at your initial ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time in people ...

BIGBANG’s G-Dragon is back—and topping music charts across the globe! On October 31 at 6 p.m. KST, G-Dragon made his long-awaited solo return with his new pre-release single “POWER.” ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Once-weekly, subcutaneous semaglutide 2.4 mg is marketed under the brand name Wegovy. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology ...

Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as ...